ArticleOncotarget2017
HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Accurate Identification of Spatial Domain by Incorporating Global Spatial Proximity and Local Expression Proximity.Biomolecules · 2024Article
- Decoding LINC00052 role in breast cancer by bioinformatic and experimental analyses.RNA biology · 2024Article
- TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis.Life science alliance · 2022Article
- Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor.Cancers · 2021Review
- LINC00052 promotes breast cancer cell progression and metastasis by sponging miR-145-5p to modulate TGFBR2 expression.Oncology letters · 2021Article
- Role of the long non-coding RNA LINC00052 in tumors.Oncology letters · 2021Review
- Integrative analysis of transcriptional profile reveals LINC00052 as a suppressor of breast cancer cell migration.Cancer biomarkers : section A of Disease markers · 2021Article
- Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer.American journal of translational research · 2020Article
- Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras.Experimental and therapeutic medicine · 2019Article
- LINC00052 suppressed glioma cell proliferation and invasion by downregulating insulin-like growth factor 2.Translational cancer research · 2019Article
- Detecting the long non‑coding RNA signature related to spinal cord ependymal tumor subtype using a genome‑wide methylome analysis approach.Molecular medicine reports · 2019Article
- EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.Oncogene · 2019Article
- Article
- Deciphering the roles of lncRNAs in breast development and disease.Oncotarget · 2018Review
- LINC00052 Promotes Gastric Cancer Cell Proliferation and Metastasis via Activating the Wnt/β-Catenin Signaling Pathway.Oncology research · 2017Article
- LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we report that the lncRNA LINC00052 expression correlates positively with HER3/ErbB3 levels in breast cancer cells. Gene silencing of LINC00052 diminished both LINC00052 and HER3 expression and reduced cancer cell growth in vitro and in vivo. LINC00052 overexpression promoted cancer cell growth in vitro and in vivo and increased HER3-mediated downstream signaling. Importantly, neutralization of HER3 signaling with HER3 targeting monoclonal antibodies blocked LINC00052 mediated cancer cell proliferation in vitro and tumor growth in vivo, suggesting LINC00052 promoting cancer growth through HER3 signaling. Taken together, our results indicate that high LINC00052 levels predict activation of HER3-mediated signaling, and LINC00052 expression level may serve as a potential biomarker for HER3 targeted antibody cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.